October 23, 2020 07:22 AM EDTUpdated October 26, 05:22 AM
Coronavirus

Covid-19 roundup: An mR­NA play­er gets a boost out of the lat­est round of an­i­mal da­ta; Phase­Bio pulls the plug on treat­ment tri­al

Nicole DeFeudis

Editor

Max Gelman

Senior Editor

John Carroll

Editor & Founder

The big tell for Cure­Vac $CVAC is com­ing up with a loom­ing ear­ly-stage read­out on their mR­NA Covid-19 vac­cine in the clin­ic. But for now …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times